Metraipolis › archive › dc_e28859c66ccd

A phase 2 trial of burosumab for treatment of fibroblast growth factor-23-mediated hypophosphatemia in children and adults with fibrous dysplasia — Europe PMC PMID:42036408

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42036408
DOI
10.1038/s41413-[numero omesso]-7
License (as archived)
solo-consultazione
Archived
2026-11-03T04:49:56.146Z
SHA-256 of the archived text
7676190f5e978a1ada6084bc7b37d891dbc080011f7c49751932a42fe542e127
Stable URL of this page
https://metraipolis.com/documento/dc_e28859c66ccd

How to cite

A phase 2 trial of burosumab for treatment of fibroblast growth factor-23-mediated hypophosphatemia in children and adults with fibrous dysplasia — Europe PMC PMID:42036408 — Europe PMC (en), https://europepmc.org/article/MED/42036408 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e28859c66ccd (Metraipolis archive dc_e28859c66ccd, sha256 7676190f5e978a1ada6084bc7b37d891dbc080011f7c49751932a42fe542e127)
BibTeX
@misc{dce28859c66ccd,
  title = {A phase 2 trial of burosumab for treatment of fibroblast growth factor-23-mediated hypophosphatemia in children and adults with fibrous dysplasia — Europe PMC PMID:42036408},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42036408},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e28859c66ccd; sha256 7676190f5e978a1ada6084bc7b37d891dbc080011f7c49751932a42fe542e127},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42036408. Agents can read the archived copy with the MCP tool read_document.